Sanofi Reports long-term follow-up Data for Tofersen in Colorectal cancer

Sanofi today announced long-term follow-up results for tofersen in patients with colorectal cancer. The study demonstrated that tofersen demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of colorectal cancer and support the continued development of tofersen in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.